Comparative Pharmacology
Head-to-head clinical analysis: IMMPHENTIV versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMMPHENTIV versus TERIFLUNOMIDE.
IMMPHENTIV vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMMPHENTIV is an anti-PD-1 monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby restoring antitumor T-cell function.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
4 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
7 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites and unchanged drug).
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category C
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."